Drug Manufacturers - Specialty & Generic
Compare Stocks
4 / 10Stock Comparison
EMBC vs ITGR vs NVCR vs LIVN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
EMBC vs ITGR vs NVCR vs LIVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $214M | $3.03B | $1.92B | $3.88B |
| Revenue (TTM) | $1.04B | $1.85B | $674M | $1.43B |
| Net Income (TTM) | $112M | $142M | $-173M | $107M |
| Gross Margin | 61.4% | 23.3% | 75.2% | 67.5% |
| Operating Margin | 27.7% | 10.4% | -27.2% | 13.4% |
| Forward P/E | 1.3x | 13.5x | — | 16.8x |
| Total Debt | $1.43B | $1.40B | $290M | $473M |
| Cash & Equiv. | $226M | $17M | $103M | $636M |
EMBC vs ITGR vs NVCR vs LIVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| Embecta Corp. (EMBC) | 100 | 10.8 | -89.2% |
| Integer Holdings Co… (ITGR) | 100 | 109.1 | +9.1% |
| NovoCure Limited (NVCR) | 100 | 20.3 | -79.7% |
| LivaNova PLC (LIVN) | 100 | 86.7 | -13.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: EMBC vs ITGR vs NVCR vs LIVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
EMBC carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (1.3x vs 16.8x)
- 10.7% margin vs NVCR's -25.7%
- 16.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend
- 10.3% ROA vs NVCR's -16.5%, ROIC 42.7% vs -16.4%
ITGR is the clearest fit if your priority is income & stability and long-term compounding.
- beta 0.72
- 165.1% 10Y total return vs LIVN's 46.2%
- Lower volatility, beta 0.72, Low D/E 80.1%, current ratio 3.32x
- Beta 0.72, current ratio 3.32x
NVCR is the clearest fit if your priority is growth exposure.
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
LIVN is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 10.7% revenue growth vs EMBC's -3.8%
- +63.0% vs EMBC's -66.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 10.7% revenue growth vs EMBC's -3.8% | |
| Value | Lower P/E (1.3x vs 16.8x) | |
| Quality / Margins | 10.7% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.72 vs NVCR's 2.20, lower leverage | |
| Dividends | 16.5% yield; 1-year raise streak; the other 3 pay no meaningful dividend | |
| Momentum (1Y) | +63.0% vs EMBC's -66.3% | |
| Efficiency (ROA) | 10.3% ROA vs NVCR's -16.5%, ROIC 42.7% vs -16.4% |
EMBC vs ITGR vs NVCR vs LIVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
EMBC vs ITGR vs NVCR vs LIVN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
EMBC leads in 3 of 6 categories
LIVN leads 1 • ITGR leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
EMBC leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ITGR is the larger business by revenue, generating $1.8B annually — 2.7x NVCR's $674M. EMBC is the more profitable business, keeping 10.7% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, LIVN holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $1.0B | $1.8B | $674M | $1.4B |
| EBITDAEarnings before interest/tax | $316M | $328M | -$165M | $220M |
| Net IncomeAfter-tax profit | $112M | $142M | -$173M | $107M |
| Free Cash FlowCash after capex | $174M | $168M | -$48M | $161M |
| Gross MarginGross profit ÷ Revenue | +61.4% | +23.3% | +75.2% | +67.5% |
| Operating MarginEBIT ÷ Revenue | +27.7% | +10.4% | -27.2% | +13.4% |
| Net MarginNet income ÷ Revenue | +10.7% | +7.7% | -25.7% | +7.5% |
| FCF MarginFCF ÷ Revenue | +16.7% | +9.1% | -7.1% | +11.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -14.4% | +0.8% | +12.3% | +14.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.9% | +172.7% | -100.0% | +106.7% |
Valuation Metrics
EMBC leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 2.2x trailing earnings, EMBC trades at a 93% valuation discount to ITGR's 30.4x P/E. On an enterprise value basis, EMBC's 3.7x EV/EBITDA is more attractive than LIVN's 15.4x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $214M | $3.0B | $1.9B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $1.4B | $4.4B | $2.1B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | 2.22x | 30.42x | -13.80x | -15.94x |
| Forward P/EPrice ÷ next-FY EPS est. | 1.28x | 13.55x | — | 16.84x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.91x | — | — |
| EV / EBITDAEnterprise value multiple | 3.73x | 13.15x | — | 15.40x |
| Price / SalesMarket cap ÷ Revenue | 0.20x | 1.64x | 2.92x | 2.79x |
| Price / BookPrice ÷ Book value/share | — | 1.79x | 5.51x | 3.22x |
| Price / FCFMarket cap ÷ FCF | 1.17x | 28.78x | — | 22.40x |
Profitability & Efficiency
EMBC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
LIVN delivers a 9.1% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-51 for NVCR. LIVN carries lower financial leverage with a 0.39x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), EMBC scores 6/9 vs LIVN's 5/9, reflecting solid financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +8.2% | -50.8% | +9.1% |
| ROA (TTM)Return on assets | +10.3% | +4.2% | -16.5% | +4.2% |
| ROICReturn on invested capital | +42.7% | +5.4% | -16.4% | +11.5% |
| ROCEReturn on capital employed | +37.8% | +6.9% | -28.9% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 5 | 5 |
| Debt / EquityFinancial leverage | — | 0.80x | 0.85x | 0.39x |
| Net DebtTotal debt minus cash | $1.2B | $1.4B | $187M | -$162M |
| Cash & Equiv.Liquid assets | $226M | $17M | $103M | $636M |
| Total DebtShort + long-term debt | $1.4B | $1.4B | $290M | $473M |
| Interest CoverageEBIT ÷ Interest expense | 39.48x | 5.07x | -96.80x | 3.98x |
Total Returns (Dividends Reinvested)
LIVN leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ITGR five years ago would be worth $9,252 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, LIVN leads with a +63.0% total return vs EMBC's -66.3%. The 3-year compound annual growth rate (CAGR) favors LIVN at 14.6% vs EMBC's -43.1% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | -67.8% | +14.5% | +28.3% | +17.0% |
| 1-Year ReturnPast 12 months | -66.3% | -26.1% | +1.1% | +63.0% |
| 3-Year ReturnCumulative with dividends | -81.6% | +8.8% | -75.7% | +50.5% |
| 5-Year ReturnCumulative with dividends | -87.6% | -7.5% | -91.3% | -14.5% |
| 10-Year ReturnCumulative with dividends | -87.6% | +165.1% | +30.3% | +46.2% |
| CAGR (3Y)Annualised 3-year return | -43.1% | +2.9% | -37.6% | +14.6% |
Risk & Volatility
Evenly matched — ITGR and LIVN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ITGR is the less volatile stock with a 0.72 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIVN currently trades 98.6% from its 52-week high vs EMBC's 23.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.72x | 2.20x | 1.29x |
| 52-Week HighHighest price in past year | $15.55 | $123.78 | $20.06 | $71.92 |
| 52-Week LowLowest price in past year | $3.45 | $62.00 | $9.82 | $39.36 |
| % of 52W HighCurrent price vs 52-week peak | +23.2% | +71.0% | +83.9% | +98.6% |
| RSI (14)Momentum oscillator 0–100 | 13.7 | 50.9 | 69.8 | 57.6 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 628K | 1.5M | 808K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: EMBC as "Sell", ITGR as "Buy", NVCR as "Buy", LIVN as "Buy". Consensus price targets imply 233.3% upside for EMBC (target: $12) vs 7.0% for LIVN (target: $76). EMBC is the only dividend payer here at 16.50% yield — a key consideration for income-focused portfolios.
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Sell | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $12.00 | $98.00 | $33.50 | $75.88 |
| # AnalystsCovering analysts | 4 | 14 | 15 | 14 |
| Dividend YieldAnnual dividend ÷ price | +16.5% | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | — |
| Dividend / ShareAnnual DPS | $0.59 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +2.7% | +1.7% | 0.0% | +0.1% |
EMBC leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). LIVN leads in 1 (Total Returns). 1 tied.
EMBC vs ITGR vs NVCR vs LIVN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is EMBC or ITGR or NVCR or LIVN a better buy right now?
For growth investors, LivaNova PLC (LIVN) is the stronger pick with 10.
7% revenue growth year-over-year, versus -3. 8% for Embecta Corp. (EMBC). Embecta Corp. (EMBC) offers the better valuation at 2. 2x trailing P/E (1. 3x forward), making it the more compelling value choice. Analysts rate Integer Holdings Corporation (ITGR) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — EMBC or ITGR or NVCR or LIVN?
On trailing P/E, Embecta Corp.
(EMBC) is the cheapest at 2. 2x versus Integer Holdings Corporation at 30. 4x. On forward P/E, Embecta Corp. is actually cheaper at 1. 3x.
03Which is the better long-term investment — EMBC or ITGR or NVCR or LIVN?
Over the past 5 years, Integer Holdings Corporation (ITGR) delivered a total return of -7.
5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ITGR returned +165. 1% versus EMBC's -87. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — EMBC or ITGR or NVCR or LIVN?
By beta (market sensitivity over 5 years), Integer Holdings Corporation (ITGR) is the lower-risk stock at 0.
72β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 206% more volatile than ITGR relative to the S&P 500. On balance sheet safety, LivaNova PLC (LIVN) carries a lower debt/equity ratio of 39% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — EMBC or ITGR or NVCR or LIVN?
By revenue growth (latest reported year), LivaNova PLC (LIVN) is pulling ahead at 10.
7% versus -3. 8% for Embecta Corp. (EMBC). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, ITGR leads at 11. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — EMBC or ITGR or NVCR or LIVN?
Embecta Corp.
(EMBC) is the more profitable company, earning 8. 8% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 8. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EMBC leads at 30. 5% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is EMBC or ITGR or NVCR or LIVN more undervalued right now?
On forward earnings alone, Embecta Corp.
(EMBC) trades at 1. 3x forward P/E versus 16. 8x for LivaNova PLC — 15. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EMBC: 233. 3% to $12. 00.
08Which pays a better dividend — EMBC or ITGR or NVCR or LIVN?
In this comparison, EMBC (16.
5% yield) pays a dividend. ITGR, NVCR, LIVN do not pay a meaningful dividend and should not be held primarily for income.
09Is EMBC or ITGR or NVCR or LIVN better for a retirement portfolio?
For long-horizon retirement investors, Integer Holdings Corporation (ITGR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
72), +165. 1% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ITGR: +165. 1%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between EMBC and ITGR and NVCR and LIVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: EMBC is a small-cap deep-value stock; ITGR is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; LIVN is a small-cap quality compounder stock. EMBC pays a dividend while ITGR, NVCR, LIVN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.